Şunu aradınız:: orplatna (Maltaca - İngilizce)

x' inhu orplatna?
what is orplatna?

kif kien mistenni li jaħdem orplatna?
how is orplatna expected to work?

għal xiex kien mistenni li jintuża orplatna?
what was orplatna expected to be used for?

orplatna huwa mediċina li fiha satraplatin bħala sustanza attiva.
orplatna is a medicine that contains satraplatin as the active substance.

orplatna kien mistenni li jintuża għat- trattament tal- kanċer tal- prostata.
orplatna was expected to be used to treat prostate cancer.

is- chmp huwa mħasseb li l- effikaċja ta ’ orplatna ma ġietx murija biżżejjed.
the chmp was concerned that the effectiveness of orplatna had not been sufficiently shown.

mistoqsija u tweġiba dwar l- irtirar ta 'l- applikazzjoni għat- tqegħid fis- suq orplatna
questions and answers on the withdrawal of the marketing application for orplatna

l- effetti ta 'orplatna għall- ewwel ġew ittestjati fuq mudelli sperimentali qabel ma ġew studjati fil - bniedem.
the effects of orplatna were first tested in experimental models before being studied in humans.

fl- 1 ta ’ awwissu 2008, pharmion ltd. uffiċjalment għarraf lill- kumitat għall- prodotti mediċinali għall- użu mill- bniedem (chmp) li tixtieq tirtira l- applikazzjoni tagħha għall- awtorizzazzjoni tat - tqegħid fis- suq għal orplatna, użata għat- trattament ta 'pazjenti li b’ kanċer tal- prostata metastatiku refrattorju għall- ormoni li l- kemjoterapija ma ħadmitx fuqhom.
on 1 august 2008, pharmion ltd. officially notified the committee for medicinal products for human use (chmp) that it wishes to withdraw its application for a marketing authorisation for orplatna, for the treatment of patients with metastatic hormone-refractory prostate cancer who have failed prior chemotherapy.